SCHEMBL740950

SCHEMBL740950

C[C@H](c1ccccc1)N1C(=O)C(C(O)C[Si](C)(C)C(C)(C)C)[C@](C)(C(=O)O)C1C(C)(C)C

nearest known ligand 0.31

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 1/20 0.31
NR3C2 P08235 4/20 0.31
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2242527 0.79 KCNA5 (0.31) KCNA5
SCHEMBL3977729 0.78 KMT2A (0.36) KCNA5KMT2A
SCHEMBL3974990 0.78 KMT2A (0.36) KCNA5KMT2A
SCHEMBL3976510 0.77 KMT2A (0.35) KCNA5KMT2A
SCHEMBL2762011 0.76 KMT2A (0.37) KMT2A
SCHEMBL741450 0.75 KCNA5 (0.34) KCNA5KMT2A
SCHEMBL2242524 0.71 KMT2A (0.36) KMT2A
SCHEMBL3977833 0.69 KCNA5 (0.33) KCNA5
SCHEMBL741115 0.69 CHRM2 (0.32) KMT2A
SCHEMBL3978378 0.68 KCNA5 (0.37) KCNA5NR3C2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138352-B2 Method for producing asymmetric tetrasubstituted carbon atom-containing compound DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-03-20 US disclosed
US-8003666-B2 Hydrate for medical purposes DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-08-23 US disclosed
US-20110144339-A1 METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-06-16 US disclosed
US-7928232-B2 Method for producing asymmetric tetrasubstituted carbon atom-containing compound DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144339-A1 METHOD FOR PRODUCING ASYMMETRIC TETRASUBSTITUTED CARBON ATOM-CONTAINING COMPOUND ACSL3, NQO2, COASY KCNA5 1371/4885NR3C2 449/4885KMT2A 2544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.